

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rekha Bansal
Serial No. : 10/716,929
Filing Date : October 19, 2003
For : METHOD OF INHIBITING FACTOR
B-MEDIATED COMPLEMENT
ACTIVATION, AND THE USES
THEREOF
Art Unit : 1644
Examiner : Francois P. Vandervegt
Attorney Docket No. : NMT-8440

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This information disclosure statement is being filed to fulfill the duty of candor and good faith toward the Patent and Trademark Office in accordance with 37 CFR §1.56.

A copy of the PTO Form 1449 has been attached.

NON-PATENT LITERATURE

Arnstead et al., "Removal of activated complement from shed blood: comparison of high-and low-dilutional haemofiltration". Acta Anaesthesiol Scand. 1998 Aug;42(7):811-5.

Buono et al., "Influence of C3 Deficiency on Atherosclerosis". Circulation 2002;105:3025-3031

Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy", Proc. Natl. Acad. Sci USA, Vol 89, pp 4285-4289, May 1992

Chenoweth, D.E., "Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med, 1981. 304(9): p. 497-503.

Clackson et al., "Making antibody fragments using phage display libraries", Nature 352, 624-628 August 15, 1991

Clardy, C.W., "Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B." Infect Immun, 1994. 62(10): pp 4549-55

Dahl et al., "MASP-3 and its association with distinct complexes of the Mannan-Binding Lectin Complement Activation Pathway", Immunity, Vol. 15, 127-135, July 2001

Dang, "Relationship between developmental stenosis of cervical spinal canal and spinal cord injury", Zhonghua Wai Ke Za Zhi, 1992 Nov;29(12):724-6, 796

Dreyer, WJ, et al. "Neutrophil accumulation in ischemic canine myocardium. Insights into time course distribution, and mechanism of localization during early reperfusion". Circulation 1991; 84:400-411

Eaton S., et al. "Assay for Plasma Complement Activation by x-ray contrast media". Invest Radiol, 1990. 25(7):p. 789-92.

Entman, Mark L., et al. "Neutrophil induced oxidative injury of cardiac myocytes", J. Clin. Invest. Vol 90, 1992, p. 1335-1345

Espinoza, Diego G. et al., "Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization", Invest Ophthalmol Vis Sci. 2003;44:3586-3592

Frederick, G.N., L. Truedsson, and A.G. Sjöholm, "New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence". J Immunol Methods, 1993; 166(2): p. 263-70

Gyoten, M., *Activation of the complement system and cytokine production by radiographic contrast media in vascular endothelial cell in vitro*, Nippon Igaki Hoshasen Gakkai Zasshi. 1998 Dec;58(14):811-5.

Halstensen TS, et al., *Local Complement activation in inflammatory bowel disease*, Immunol Res. 1991; 10(3-4): 485-92.

Halstensen TS, et al., *Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis*, Gastroenterology. 1990 May;98(5 pt 1):1264-71.

Hikawa, Maoshi, et al., *Method for production of neuronal hybridoma using emetine and actinomycin D*, Brain Research Protocols 1 (1997) 224-226.

Horiuchi, T., et al., *Human complement factor B: cDNA cloning, nucleotide sequencing, phenotypic conversion by site-directed mutagenesis and expression*. Mol Immunol, 1993. **30**(17): p. 1587-92.

Hourcade, D.E., L.M. Wagner, and T.J. Oglesby, *Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis*. J Biol Chem, 1995. **270**(34): p. 19716-22.

Ikeda, Ken et al., *Serum lectin with known structure activates complement through the classical pathway*, Journal of Biological Chemistry. 1987 262(16): p. 7451-7454

Isaacs, J.D., et al., *Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential*. J Immunol, 1992. **148**(10): p. 3062-71.

Jones HM, et al., *Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways.*, Anaesthesia. 1982 Jun;37(6):629-33.

Jones, Peter T. et al., *Replacing the complementarity-determining regions in a human antibody with those from a mouse*, Nature 321, 522-525, May 29, 1986

Kawana S. et al., *Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis*, Arch Dermatol Res. 1990;282(3):187-7.

Kilpatrick, David C., *Mannan-Binding lectin: clinical significance and applications*, Biochimica et Biophysica Acta 1572 (2002) 401-413.

Kitano A., et al., *New treatment of ulcerative colitis with k-76*, Dis Colon Rectum. 1992 Jun;35(6):560-7.

Kolios G. et al., *Mediators of inflammation: production and implication in inflammatory bowel disease*. Hepatogastroenterology. 1998 Sept-Oct;45(23):1601-9.

Lonberg Nils, et al., *Antigen-specific human antibodies from mice comprising four distinct genetic modifications*, Nature 368, 856-859: April 28, 1994.

Marks, J.D. et al., *By-passing immunization. Human antibodies from v-gene libraries displayed on phage*, J Mol Biol. 1991 Dec5;222(3):581-597.

Moore, F.D., Jr., et al., *The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution*. Ann Surg, 1988. **208**(1): p. 95-103.

Morgan BP et al., *Measurement of terminal complement complexes in rheumatoid arthritis*, Clin Exp Immunol. 1998 Sep;73(3):473-8.

Morgan BP, Walport MJ, *Complement deficiency and disease*, Immunol Today. 1991 Sep;12(9):301-6.

Morrison SL et al., *Chimeric human molecules: mouse antigen-binding domains with human constant region domains*, Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5.

Nakano S, Engel AG, *Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients*, Neurology. 1993 Jun;43(6):1167-72.

Niculescu F, Rus H. *Complement activation and atherosclerosis*, Mol Immunol. 1999 Sep-Oct;36(13-14):949-55.

Pack P. et al., *Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli*, Biotechnology (NY). 1993 Nov;11(11):1271-7.

Pangburn, M.K., R.D. Schreiber, and H.J. Muller-Eberhard, *Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3*. J Exp Med, 1981. **154**(3): p. 856-67.

Polhill, R.B., Jr., K.M. Pruitt, and R.B. Johnston, Jr., *Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses*. J Immunol, 1978. **121**(1): p. 363-70.

Ravetch, J.V. and J.P. Kinet, *Fc receptors*. Annu Rev Immunol, 1991. **9**: p. 457-92.

Sandhu JS, *Protein engineering of antibodies*, Crit Rev Biotechnol. 1992;12(5-6):437-62.

Schafer Hansjorg, et al. *Deposition of the Terminal C5b-9 Complement Complex in infarcted areas of human Myocardium*, Journal of Immun. 1986; 137(6); p. 1945-1949

Schmiedt, Walther et al., *Complement C6 Deficiency Protects Against Diet-Induced Atherosclerosis in Rabbits*, Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.

Schulze, M. et al., *Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis*, Am J Pathol. 1993 Jan;142(1):179-87.

Seifert PS, et al. *Isolation and characterization of a complement-activating lipid extracted from human atherosclerosis lesions*, J Exp Med. 1990 Aug 1;172(2):547-57.

Seifert PS, et al., *Generation of Complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position*, Mol Immunol. 1987 Dec;24(12):1303-8.

Seifert PS, et al. *The complement system in atherosclerosis*, Atherosclerosis. 1988 Oct;73(2-3):91-104.

Singer II, et al., *Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences*, J Immunol. 1993 Apr 1;150(7):2844-57.

Stevens, John H., et al. *Effects of anti-C5a antibodies on the Adult Respiratory Distress Syndrome in Septic Primates*, 1986. 77: p. 1812-1816.

Tada, T. et al., *Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction*, Virchows Archiv, 1997. 430(4): p. 327-332.

Takabayashi T., et al., *A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis*, J Immunol. 1996 May 1;156(9):3455-60.

Theil, Steffen et al., *Interaction of C1q and Mannan-Binding Lectin (MBL) with C1r, C1s, MBL-Associated Serine Proteases 1 and 2, and the MBL-Associated Protein MA919*, J. Immunol 2000. 165:878-887.

Tomooka K., *Serum complement levels in patients with rheumatoid arthritis and vasculitis*, Fukuoka Igaku Zasshi. 1989 Oct;80(10):456-66.

Utey, J.R., *Pathophysiology of cardiopulmonary bypass: current issues*. J Card Surg, 1990. 5(3): p. 177-89.

van de Winkel, J.G. and P.J. Capel, *Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications*. Immunol Today, 1993. 14(5): p. 215-21.

Vaughan, T.J., J.K. Osbourn, and P.R. Tempest, *Human antibodies by design*. Nat Biotechnol, 1998. 16(6): p. 535-9.

Woodruff Trent M., et al., *A Potent Human C5a Receptor Antagonist Protects against disease Pathology in a Rat Model of Inflammatory Bowel Disease*, J. Immunol. 2003. 171:5514-5520

Yasojima, K. et al., *Complement Components, but not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques*, Arterioscler. Thromb. Vasc. Biol. 2001;21;1214-1219.

Ames, R.S., et al., *Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models*. J Immunol, 2001. 166(10): p. 6341-8.

Hulett, M.D. and P.M. Hogarth, *Molecular basis of Fc receptor function*. Adv Immunol, 1994. 57: p. 1-127.

Lin, Y.F., et al., *Cytokine production during hemodialysis: effects of dialytic membrane and complement activation*. Am J Nephrol, 1996. 16(4): p. 293-9.

Liszewski, e.a.T.C.S.I.F.I., Third Edition, pp. 917-939. W. E. Paul (Ed.). Raven Press: New York.

Respectfully submitted,

/Richard A. Sutkus/
Richard A. Sutkus
Reg. No. 43,941

TAROLLI, SUNDHEIM, COVELL,
& TUMMINO L.L.P.
1300 East Ninth Street, Suite 1700
Cleveland, Ohio 44114
Phone:(216) 621-2234
Fax: (216) 621-4072
Customer No.: 68,705